How regional innovation clusters support national growth

The rise of regional life sciences ecosystems

Regional innovation clusters have become a defining feature of the UK life sciences landscape. These clusters bring together universities, NHS organisations, research institutes and industry partners, creating environments in which discovery, development and commercialisation can thrive. While London and the South East remain significant centres of activity, regions such as the Midlands, the North West and Scotland have continued to strengthen their presence. Each cluster develops its own character shaped by local expertise, infrastructure and collaboration patterns, and together they form a national network that underpins the sector’s competitiveness.

Clusters as engines of economic activity

Life sciences clusters play a central role in generating economic growth and high quality employment. By concentrating expertise and resources, they create conditions that attract investment and support the development of new companies. Businesses often locate within clusters to gain access to skilled workers, specialist facilities and knowledge exchange opportunities. This concentration of activity can stimulate supply chains, encourage entrepreneurial activity and support the broader economic ambitions of their regions. As clusters grow, they contribute not only to local prosperity but also to the overall strength of the national life sciences sector.

The presence of well established academic institutions within these clusters is particularly important. Universities provide a continuous flow of scientific talent and contribute to the research that fuels innovation. Partnerships between academia and industry help translate discoveries into practical applications, ensuring that breakthroughs move efficiently from laboratories into clinical and commercial settings. This dynamic relationship supports both scientific progress and regional economic development, demonstrating how closely research excellence and industrial growth are connected.

Collaboration as a foundation for success

At the heart of each cluster is collaboration. Organisations work together to share expertise, infrastructure and insights, creating an environment in which collective progress is prioritised. This collaborative culture allows clusters to respond more effectively to emerging needs, whether they involve new technologies, workforce development or changes in regulatory requirements. For example, partnerships between local colleges, universities and employers help shape programmes that prepare students for sector specific roles. Such cooperation ensures that training aligns with industry expectations and supports the development of a skilled workforce capable of meeting future demand.

Collaboration also strengthens the ability of clusters to secure funding for large scale research programmes and infrastructure projects. By presenting a unified vision and demonstrating strong partnerships, clusters can make a compelling case for investment. This helps support the development of advanced research facilities, manufacturing capabilities and clinical testing infrastructure, all of which are essential for a competitive life sciences environment. The benefits of these investments extend beyond the immediate region, contributing to the UK’s broader scientific and economic capacity.

Supporting innovation through shared infrastructure

Shared infrastructure is one of the key advantages that clusters offer. Facilities such as incubators, laboratories, manufacturing units and clinical research centres provide organisations with access to capabilities that might otherwise be out of reach. These shared resources reduce barriers to entry for smaller companies and encourage experimentation and early stage development. They also create physical spaces that bring researchers, clinicians and entrepreneurs into closer contact, promoting informal knowledge exchange and sparking new collaborations.

In many regions, NHS organisations play a central role in this shared infrastructure. Their involvement supports clinical trials, translational research and the adoption of new technologies in real world settings. This integration between research and healthcare delivery allows clusters to test innovations quickly and generate evidence that informs further development. It also strengthens the UK’s ability to conduct clinical research at scale and maintain a steady pipeline of therapies and technologies that can benefit patients nationwide.

A platform for balanced national growth

One of the most significant contributions of regional clusters is their role in supporting balanced national growth. By fostering strong life sciences ecosystems outside traditional centres, clusters help distribute economic opportunity more evenly across the UK. This supports wider policy objectives related to regional development and ensures that the benefits of life sciences investment extend to diverse communities. Clusters also contribute to the resilience of the national sector by spreading risk and creating multiple hubs of innovation that can adapt to changing circumstances.

Their success highlights the importance of place based strategy in life sciences planning. Recognising the distinct strengths of different regions allows policymakers and investors to support growth where it is most likely to flourish. This approach reinforces the idea that national success is built upon the strengths of local ecosystems. Each cluster adds to the collective capability of the UK, whether through specialisation in advanced therapies, diagnostics, manufacturing or clinical research.

Looking ahead to sustained growth

The continued development of regional innovation clusters will depend on sustained collaboration, investment and strategic planning. Ensuring that each cluster has access to skilled workers, modern infrastructure and strong research partnerships remains a priority. As technologies evolve and the demands on the sector increase, clusters will need to adapt while preserving the cooperative foundations that underpin their success.

What is clear is that regional clusters are more than local hubs of activity. They are strategic assets that contribute directly to the UK’s life sciences ambitions. By strengthening these ecosystems, the UK can enhance innovation, support high value employment and build a more resilient and balanced national sector. The path forward rests on advancing the partnerships, infrastructure and shared vision that have enabled clusters to flourish.

Author

Leave A Comment

Shabna Raja

Advisory Partner,
Life Sciences Week
+44 (0) 121 227 4156
info@lifesciencesweek.co.uk

Bio

Shabna Raja is a senior leader in enterprise transformation within Life Sciences, with over 20 years’ experience spanning pharma, consumer health and large-scale digital programmes.

She specialises in bridging strategy and execution – helping organisations translate AI, data and digital innovation into tangible business outcomes. Her work focuses on complex transformation
initiatives across commercial, data and operating model domains within regulated environments.

Shabna spent seven years at GSK, where she played a key role in transformation programmes, including as part of the Consumer Health joint venture with Pfizer — one of the most significant integrations in the sector. This experience provided her with deep expertise in  organisational change, integration and operating model evolution at global scale.

More recently, she has spent over three years working closely with Haleon through a strategic
services partnership, leading enterprise client engagement and managing a multi-million-pound account while supporting transformation across a newly independent global organisation.

Her experience spans the end-to-end life sciences value chain, including R&D, commercial, supply chain and patient engagement, giving her a holistic perspective on how technology and transformation can unlock value across the industry.

Amjad Khan

Executive Partner,
Life Sciences Week
+44 (0) 121 227 4156
info@lifesciencesweek.co.uk

Bio

Amjad Khan is a UK-based entrepreneur, AI strategist, and senior technology leader with over 15 years of experience at Pfizer, where he held multiple leadership roles across digital strategy and transformation. As Global Digital Client Partner, he was responsible for digital strategy and execution across Global Business Units covering Vaccines, Hospital, and Medical Affairs. Most notably, he led the commercial launch for the Covid franchise transforming and accelerating the model for how new medicines are brought to market.

Following his tenure at Pfizer, Amjad channelled his expertise into building at the frontier of AI. His work spans AI leadership, stakeholder engagement, and agile delivery helping organisations adopt
and scale emerging  technologies to drive meaningful outcomes.

Dr. Richard Fallon | Business Consultant | WM Life Sciences

Dr. Richard Fallon

Co Founder, Life Sciences Week 
+44 (0) 121 227 4156
info@lifesciencesweek.co.uk

Bio

Dr Richard Fallon is an entrepreneur and ecosystem builder who connects industry leaders, investors and public-sector stakeholders to accelerate collaboration and commercial growth.

As the Founder of the Technology Supply Chain and co-founder of the Innovation Awards, he has spent more than two decades convening influential networks that help emerging businesses find capital, strategic partners and new routes to market.

Richard’s work spans leadership and consultancy across major organisations, alongside building membership and partnership platforms that bring universities, industry and investors into the same room – and turn conversations into practical outcomes.

With his focus on life sciences, Richard supports organisations and people driving breakthroughs in healthcare, biotechnology, medical technology and advanced research. He is passionate about creating the conditions for transformative ideas to move from concept to real-world impact – by connecting innovators with the funding, expertise and opportunities they need to scale.

Through Life Sciences Week, Richard is championing the UK’s world-class life sciences community and helping position it at the forefront of innovation, investment and patient outcomes.

Paul Cadman | Executive Chairman | WM Life Sciences

Prof Paul Cadman

CEO of One Thousand Trades Group & Co-founder of Life Sciences Week,
Life Sciences Week
+44 (0) 121 227 4156
info@lifesciencesweek.co.uk

Bio

Prof. Paul Cadman is a nationally and internationally recognised, award-winning inclusive leader and “knowledge broker”, known for bringing people, ideas and organisations together to turn ambition into deliverable outcomes.

His experience spans Research, Technology, Manufacturing, Consultancy and Membership Organisations – giving him a rare ability to translate between sectors, priorities and professional cultures in a way that builds trust and unlocks progress.

Across his career, Paul has helped take concepts from inception through to scale, including initiatives that have generated £100m+ in turnover. He combines strategic thinking with an extensive network, supporting organisations to drive organic growth, forge partnerships and deliver meaningful business transformation. He is particularly valued for his ability to connect the right stakeholders at the right time, and create the conditions for collaboration to become action.

Through Life Sciences Week, Paul helps convene the communities shaping innovation – bringing together research, industry and investment to strengthen relationships, spotlight opportunity, and accelerate real-world impact.

Amy Deakin | Chief of Staff | WM Life Sciences

Amy Deakin

Event Managing Director,
Life Sciences Week
+44 (0) 121 227 4156
info@lifesciencesweek.co.uk

Bio

Amy Deakin is a Birmingham-based leader specialising in building partnerships and fostering innovation in the life sciences sector. With a degree in Sport and Exercise Science, Amy brings a grounded understanding of human health and performance to her work and a strong interest in the developments shaping healthcare today.

Amy is Managing Director of Life Sciences Week, part of the One Thousand Trades Group, and also serves as Director of One Thousand Trades Events. In these roles, she convenes researchers, clinicians and industry leaders to strengthen collaboration, unlock new partnerships and help accelerate real-world innovation across the life sciences ecosystem.

Her career spans both commercial and third-sector environments. She began in automotive design, delivering projects for Volkswagen, McLaren, Bentley and Jaguar Land Rover, before moving into the third sector with Acorns Children’s Hospice. She later joined Western Union, working as a Partnerships Manager for international payments

An avid netballer, Amy is a committed advocate for health and wellbeing – bringing energy, clarity and connection to everything she builds, and actively involved as a participant in health related research studies.

    Award Category Voting

    Here's a list of all categories you can vote for. Simply click each category to cast your vote. Voting in each category is not mandatory, so please feel free to click just the category that interests you.

    Day you've not voted in, will be denoted with an ❌

    If you're having issues submitting the form, please ensure all the category boxes are closed and try again.

    Recognising pioneering research, technology, or therapies that are transforming healthcare and biotechnology.

    No VoteProf. Alex RichterBlack Space TechnologyAston Vision Sciences

    Celebrating an emerging leader making significant contributions to the field through research, innovation, or leadership.

    Recognising pioneering research, technology, or therapies that are transforming healthcare and biotechnology.

    No VoteShashank Chaganty – VichagLeah Vanono - PBS InnovationsKloe Avon- KZ Organics

    Honouring successful cross-sector partnerships driving advancements in life sciences, from academia to industry.

    No VoteProf Liam Grover- WMHTIAJudith Stewart- Health Innovation West MidlandsAdam McGuinness - Plug and Play

    Awarding an individual or organisation for exceptional long-term impact on the industry.

    No VoteDavid KidneyMedilink MidlandsUniversity of Birmingham

    Highlighting innovations in treatments, diagnostics, or healthcare delivery that have significantly improved patient outcomes.

    No VoteJean-Louis Duprey - Linear DiagnosticsSian Dunning - MD-TECKarim Vissangy - HoloMedix

    Your Details